Arrowhead rises on new Phase IIa HBV data

Arrowhead Research Corp. (NASDAQ:ARWR) gained $0.45 to $7.19 after it said ARC-520 reduced circulating hepatitis B surface antigen (HBsAg) levels by a maximum of 99% in treatment-naive patients with HBV infection in a Phase IIa study.

In six treatment-naive, HBV e-antigen (HBeAg)-positive patients, Arrowhead said a single dose of 4 mg/kg ARC-520 produced a mean maximum HBsAg reduction of 1.05 log (91%) through 15 days, with a best peak reduction of 1.9 log (99%). ...